Navigation Links
Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk
Date:5/1/2008

Heart specialists at Johns Hopkins and elsewhere report what is believed to be the first wide-scale evidence linking severe overweight to prolonged inflammation of heart tissue and the subsequent damage leading to failure of the bodys blood-pumping organ.

The latest findings from the Multiethnic Study of Atherosclerosis (MESA), to be published in the May 6 issue of the Journal of the American College of Cardiology, appear to nail down yet one more reason for the estimated 72 million obese American adults to be concerned about their health, say scientists who conducted the research.

The biological effects of obesity on the heart are quite profound, says senior study investigator Joo Lima, M.D. Even if obese people feel otherwise healthy, there are measurable and early chemical signs of damage to their heart, beyond the well-known implications for diabetes and high blood pressure.

He adds that there is now even more reason for them to lose weight, increase their physical activity and improve their eating habits.

In the latest study, researchers conducted tests and tracked the development of heart failure in an ethnically diverse group of nearly 7,000 men and women, age 45 to 84, who were enrolled in the MESA study, starting in 2000.

Of the 79 who have developed congestive heart failure so far, 35 (44 percent) were physically obese, having a body mass index, or BMI, of 30 or greater. And on average, obese participants were found to have higher blood levels of interleukin 6, C-reactive protein and fibrinogen, key immune system proteins involved in inflammation, than non-obese adults.

A near doubling of average interleukin 6 levels alone accounted for an 84 percent greater risk of developing heart failure in the study population.

The researchers from five universities across the United States also found alarming links between inflammation and the dangerous mix of heart disease risk factors known as
'/>"/>

Contact: David March
dmarch1@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. High blood pressure still sneaking past doctors, Stanford study shows
2. Study by Texas A&M University-Corpus Christi Confirms Training With Vision Software Enhances Hitting Skills
3. Canary Foundation and the National Cancer Institute Launch New Prostate Cancer Study
4. Largest study to date finds benefits of ICDs in children
5. Study shows power of police and fire officers as injury-prevention messengers
6. Study raises questions about prostate cancer therapies targeting IGF-1
7. Children More Vulnerable to Harmful Effects of Lead at Age 6 Than as Toddlers, Says New Study
8. Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers
9. Penn study finds elderly heart patients with ICD devices live longer after heart failure
10. Physical activity, healthy eating and BMI not linked in older teens: study
11. Salk study links diabetes and Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:CoorsTek Holds Grand Opening for Newest Facility in South Korea 2Health News:CoorsTek Holds Grand Opening for Newest Facility in South Korea 3Health News:Don't Wait for the Election to Plan Your Long-Term Healthcare, Insurance Leader Advises 2Health News:Chemo for Mesothelioma Offers Limited Survival Benefits 2Health News:dLife Launches the World's Largest and Most Comprehensive Online Food and Diabetic Recipe Search Tool 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Express Scripts Launches Equity Offering to Finance Acquisition 47588 1Express Scripts Launches Equity Offering to Finance Acquisition 47588 2Express Scripts Launches Equity Offering to Finance Acquisition 47588 3Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 1Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 2Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 3Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 4Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 5Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 1Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 2Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 3
Other Medicine Technology:Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 2Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 3Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 4Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 5Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5